BEVERLY, Mass., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCBB:CTIX) today announced that it has successfully completed a study with its proprietary compound, KM-133, in a human xenograft animal model of psoriasis. The study showed that KM-133 reduced psoriasis more than controls (p<0.01). The higher of two doses of KM-133 reduced psoriasis more than methotrexate (p<0.01). Psoriasis did not recur with KM-133 during the entire course of the experiment, whereas psoriasis reoccurred in the group of animals treated with methotrexate after an average of 61 days. The study also looked at histological indications of psoriasis as well as three bio-markers, PRINS, IL-20 and 12-R lipoxygenase, and found that KM-133 had significant effects on all these parameters. Weight losses for the KM-133 treated animals were within acceptable limits.
